(Q36670466)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

review article

1 reference

title

Post-therapy changes in PSA as an outcome measure in prostate cancer clinical trials (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

4

Howard I Scher

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Mark T Fleming

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

Glenn Heller

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Oncology

22 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

658-667

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

Surrogate end points in clinical trials: are we being misled?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

Clinical states in prostate cancer: toward a dynamic model of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

The influence of finasteride on the development of prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Prostate cancer with low PSA levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Intermediate end point for prostate cancer-specific mortality following salvage hormonal therapy for prostate-specific antigen failure

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Clinical trials in relapsed prostate cancer: defining the target

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Natural history of progression after PSA elevation following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

A critical analysis of response criteria in patients with prostatic cancer treated with CIS-diamminedichloride platinum II

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Lack of correlation between prostate-specific antigen and the presence of measurable soft tissue metastases in hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

High-dose intravenous estrogen therapy in advanced prostatic carcinoma. Use of serum prostate-specific antigen to monitor response.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Surrogate endpoints in clinical trials: definition and operational criteria

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Flutamide versus prednisone in patients with prostate cancer symptomatically progressing after androgen-ablative therapy: a phase III study of the European organization for research and treatment of cancer genitourinary group

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Suramin-induced decrease in prostate-specific antigen expression with no effect on tumor growth in the LNCaP model of human prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

The promise and peril of surrogate end points in cancer research

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Biology of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Antiangiogenic activity of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Serum insulin-like growth factor binding protein-3/prostate-specific antigen ratio is a useful predictive marker in patients with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Dissociation between androgen responsiveness for malignant growth vs. expression of prostate specific differentiation markers PSA, hK2, and PSMA in human prostate cancer models

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Androgen-Independent Prostate Cancer Is a Heterogeneous Group of Diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Weekly high-dose calcitriol and docetaxel in metastatic androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update.

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0664

7 January 2021

Identifiers

DOI

10.1038/NCPONC0664

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17139317%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference